A new report has found that emerging companies, most with no presence in Australia, are responsible for over 90 per cent of gene, cell and nucleotide therapies currently in late-stage pipelines. …
Latest Video
New Stories
-
September agenda puts cancer drugs, RSV prevention and ADHD access in focus
August 31, 2026 - - Latest News -
A decade is more than enough - the case for term limits on advisory committees
August 31, 2026 - - Latest News -
Expansion opens PBS access for more with advanced cancer, but it took a long time
August 31, 2026 - - Latest News -
Sanofi leader urges Australia to look beyond the laboratory in building vaccine capability
August 31, 2026 - - Latest News -
Astellas Australia turns to rare disease leader Guillaume Pfeiffer for next chapter
August 31, 2026 - -
Funding brings a new targeted treatment for Australians with lupus kidney disease
August 31, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - Series 5. Ep.30
August 28, 2026 - - Podcast